Top Biotechnology Startups in 2027

Revance is a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, as well as financial technology services for aesthetic practices.

80% of our immune system lives in the gut. And this is established in the first 1,000 days of life. Tiny Health is the first at-home gut health testing company developed for expecting moms and babies 0-3 years of age, which dictates the child's lifelong health and potential risks for eczema, allergies, asthma, autism and other chronic diseases later in life. Processed in a CLIA-certified lab and using proprietary technology, our test provides strain-level precision and a complete list of ALL microbes in your gut and vaginal microbiomes - any bacteria, fungi, parasites, archaea, and viruses. Every report includes a personalized interpretation and is reviewed by a team of microbiologists, immunologists and maternal/pediatric nutritionists. More importantly, Tiny Health provides actionable, evidence-based insights and recommendations based on results, to give each baby the best possible start in life. Tiny is the best and most affordable test for parents to monitor and optimize their baby’s gut health development in those crucial early years. We are backed by the top founders and operators in technology and health from Coinbase, GoogleX, TrendMD, StartX Med, Hinge Health, Calm, Signos, Roblox, Walmart Labs, Dropbox, Recogni, Awesome People Ventures, Wisdom Partners and Parenthood Ventures - as well as The Venture City, Conscience VC, Polymath Capital, Hustle Fund, and OnDeck Runway.

Sema4 is a next-generation health information company, spun out of the Mount Sinai Health System, that provides advanced genomic testing and merges big data analytics with clinical diagnostics. Our team creates practical tools that help patients, clinicians, and researchers better diagnose, treat, and prevent disease. We are striving to construct a more comprehensive picture of health by integrating three key elements: a wealth of clinical experience that informs the answers that patients and providers are seeking, the world-class academic research that illuminates new directions, and the pioneering information science that puts all the pieces together.

The architectures that power modern AI were designed for language, not for science. They were never built to understand DNA, interpret experiments, or learn the rules that govern living systems. Closing this gap represents one of the defining opportunities of our time. Our team has pioneered advances across frontier AI, including the first models trained with one-million-token context windows, and now scaling toward one billion. We focus on innovations on systems and architecture, because building AI for science demands a fundamentally different foundation. As a first application of this technology engine, we are advancing AI for life, the most complex and consequential domain of all. We are the AI team behind Evo and Evo 2, the generative genomics models used to create real gene-editing tools and the first whole genomes designed entirely by AI. That work demonstrated that AI can create biology, not just analyze it. We are now building multimodal models trained directly on the fabric of biology, enabling faster discovery, deeper understanding, and entirely new capabilities. As we push the frontier of scientific world models, we will build systems hand-in-hand to ensure global biological resilience: rapid detection, rapid response, and rapid countermeasures against emerging threats, both natural and synthetic. Our mission is ambitious: to reimagine what AI can do for science, and to build that future.

Founding team is: - Dr. Ilya Rachman - MD PhD MBA and practicing clinician of over 10 years. - Dr. Vladimir Torchilin - worldwide expert in nanotechnology and pharmacology. Times Higher Education ranked V.Torchilin as #2 among world top scientists in pharmacology for the years 2001-2010. V.Torchilin has published over 350 original papers, over 150 reviews, wrote and edited 10 books and holds over 40 patents. Former Head of Chemistry Program, Center for Imaging and Pharmaceutical Research at Harvard Medical School and MGH. - Sean Senn - Chair of Archer Norris' patent practice and Head Fund Manager of The Archer Fund archernorris.com/Attorneys/AttorneysPZ/senn

Our Company: Genista Biosciences is a rapidly growing biotech company based in San Jose, CA that is dedicated to improving public health and food safety, both on the community and global scale. Our Goal: To revolutionize food safety by creating a cutting-edge platform based on a unique combination of robotics, software, and technology. Our ability to offer fast and accurate testing while still being cost-effective allows every member of the food supply chain (big or small) to be rest assured that the food they produce is safe thereby making the world a better place.

At IndieBio, we are committed to building a future where biology is not only a field of study, but a technology that will help solve our world’s most challenging problems. We are part of SOSV, one of the world's top early-stage investors, and our three-month programs are designed to put founders side-by-side every day with technical experts as well as provide $500,000 in capital to ensure a fast start for world shaping ideas. Graduates of IndieBio benefit from the remarkable IndieBio community as well as well as ongoing SOSV investment through A, B and later rounds. We have locations in New York City and San Francisco. If you are driven to change the world around you, then stop waiting: APPLY NOW!

We have extensive expertise in method development, validation, and transfer, mass spectrometric and chromatographic (LC-MS) bioanalysis, pharmacokinetics (PK) sample analysis, toxicokinetic safety testing, as well as other custom assay services. Our assay services include ELISA based assay, cell-based assay, biomarker testing, immunogenicity testing, biochemical assay, and Mechanism of Action (MoA) studies.

10x Genomics (NASDAQ: TXG) is one of the fastest growing biotech companies, growing from $3M in revenue in 2015 to $240M in 2019. We create hardware, chemistry, and software that accelerates biological research. Our products are used by scientists around the world, including 96 of the top 100 global research institutions. Our mission is to build products that will be used throughout the rest of this century, to better understand, and eventually conquer disease. Behind every breakthrough is an extensive network of talented individuals contributing their unique perspectives, backgrounds, and areas of expertise. This kind of collaboration is essential to building a strong and effective workplace, and it’s our goal to create an inclusive environment that reflects the diversity of the communities and the goals that we serve. The discoveries we make now, as a team, will lead to better technologies, better treatments, and a better future.